Jessica Steen
Optometrist · Davie, FLNPI 1649688847
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 41.7% of the total. 2025 is the largest year on record at $121,832, more than ten times the $1,098 reported in 2019. Among optometrist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $599.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$107K
- Oyster Point Pharma, Inc.$59K
- Alcon$48K
- Carl Zeiss Meditec, Inc.$11K
- AbbVie$10K
- Alcon Research LLC$8K
- plus $13K from 23 others
What the payments were for
- Consulting fees$62,11024%
- Speaking & faculty fees$149,24558%
- Travel & lodging$28,80211%
- Food & beverage$15,9606%
- Other$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 127 | $106,848 |
| Oyster Point Pharma, Inc. | 102 | $58,768 |
| Alcon | 81 | $47,687 |
| Carl Zeiss Meditec, Inc. | 17 | $11,372 |
| AbbVie(2 entities) | 26 | $10,037 |
| Alcon Research LLC | 5 | $8,152 |
| Thea Pharma Inc. | 8 | $4,391 |
| Astellas Pharma US Inc | 3 | $1,800 |
| Tarsus Pharmaceuticals, Inc. | 4 | $1,174 |
| Glaukos Corporation | 5 | $1,054 |
| Johnson & Johnson Vision Care, Inc. | 9 | $819 |
| Dompe US, Inc. | 6 | $464 |
| LKC Technologies, Inc. | 1 | $450 |
| Sun Pharmaceutical Industries Inc. | 7 | $428 |
| Aerie Pharmaceuticals, Inc. | 4 | $413 |
| Kala Pharmaceuticals, Inc. | 3 | $345 |
| Topcon Healthcare, Inc. | 1 | $300 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $286 |
| Optovue, Inc. | 3 | $249 |
| Carl Zeiss Meditec USA, Inc. | 1 | $230 |
| Amgen(2 entities) | 2 | $225 |
| Visionix USA, Inc | 2 | $141 |
| Harrow Eye, LLC | 1 | $130 |
| Novartis | 1 | $125 |
| Optos, Inc. | 1 | $99 |
| Coopervision Inc. | 1 | $68 |
| Ocular Therapeutix, Inc. | 1 | $50 |
| Baxter Healthcare | 1 | $28 |
| Spark Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$63,240
- TYRVAYA$56,841
- XIIDRA$55,235
- VYZULTA$39,363
- Rocklatan$33,805
- Rhopressa$33,704
- TRYPTYR$14,550
- CIRRUS HD-OCT$12,052
- SIMBRINZA$11,110
- LUMIGAN$5,693
- LOTEMAX SM$5,524
- CLARUS$4,963
- CIRRUS 6000 with AngioPlex$4,791
- FORUM$3,933
- CIRRUS 5000 with AngioPlex$3,721
- Humphrey Field Analyzer (HFA3)$3,010
- VisuMax$2,666
- CIRRUS AngioPlex$2,341
- QUATERA 700$2,275
- Retina Workplace$1,970
How this compares
$256,145 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 95 | $29,627 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $11,872 |
| RhopressaNetarsudil Mesylate | 23 | $8,913 |
| Latanoprost | 150 | $1,309 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 73 | $1,028 |
| Brimonidine Tartrate | 66 | $423 |
| Timolol Maleate | 27 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $10,037 | $29,62795 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $413 | $20,78459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Davie
- Calista MingDavie$78K
- Chandra MicklesDavie$68K
- Sherrol ReynoldsDavie$60K
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Nora CothranLargo$505K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
- Karen HoffmanOrange Park$282K
- Ashley RothMiami Beach$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.